Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

After reaching an important support level, Vigil Neuroscience, Inc. (VIGL) could be a good stock pick from a technical ...

Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational ...

Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Vigil Neuroscience shares jumped nearly 250% Thursday after the Alzheimer's disease drug developer reached a deal to be ...

Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

About a year after investing in Vigil Neuroscience Inc., Sanofi is now acquiring the Watertown biotech and its treatment in ...

The latest price target for Vigil Neuroscience (NASDAQ:VIGL) was reported by Stifel on May 28, 2025. The analyst firm set a price target for $8.00 expecting VIGL to rise to within 12 months (a ...

After reaching an important support level, Vigil Neuroscience, Inc. (VIGL) could be a good stock pick from a technical perspective. VIGL recently experienced a "golden cross" event, which saw its ...

Sanofi SAN-5.48%decrease; red down pointing triangle said it entered an agreement to acquire Vigil Neuroscience VIGL-0.13%decrease; red down pointing triangle for approximately $470 million ...